A national Gallup poll shows that the use of GLP‑1 injectable weight‑loss medications among Americans has reached a record high, increasing nearly fourfold since 2024.
A retrospective analysis published in the Journal of the American Heart Association found that patients with type 2 diabetes and peripheral artery disease who were treated with GLP‑1 receptor agonists experienced lower rates of mortality, major amputations, revascularization procedures, and hospitalization.
A cohort study reported in JAMA Network Open indicated that initiating continuous glucose monitoring in primary‑care settings improves glycemic control and reduces hospital visits for patients who rely on insulin.
In a crossover trial described in eBioMedicine, acute high‑intensity interval exercise suppressed energy intake and raised metabolic markers among participants with overweight or obesity.
Steroid androgen profiling data suggest that endometriosis may be an androgen‑dependent condition, according to research published in the European Journal of Endocrinology.
A cohort study in the Journal of Clinical Endocrinology & Metabolism found that children conceived within six months of their mother undergoing hysterosalpingography scored lower on mean IQ, information‑processing, and attention‑control tests than children conceived without fertility treatments.
A randomized trial involving children and young people with type 1 diabetes in low‑resource settings, reported in Lancet Diabetes & Endocrinology, found that long‑acting insulin glargine did not provide a superior outcome compared with intermediate‑acting human insulin.
Retrospective data published in JAMA Network Open reveal that long‑term health‑care costs are higher for patients with obesity and diabetes who are treated with GLP‑1 medications than for those who undergo bariatric surgery.
Real‑world data from Truveta indicate that users of oral semaglutide (Wegovy) typically adhere to the manufacturer’s recommended starting dose and titration schedule.
Kailera Therapeutics reported that its investigational oral GLP‑1 candidate HRS‑7535/KAI‑7535 achieved its primary endpoints in two Chinese phase III trials—one evaluating adults with overweight or obesity and another assessing adults with type 2 diabetes.
![Calf Strains Recur in Elite Soccer: The Challenge of Christian Pulisic’s Injury [TITLE]](https://i1.wp.com/d.medicaldaily.com/en/full/483058/christian-pulisic.jpg?w=1024&resize=1024,1024&ssl=1 "Calf Strains Recur in Elite Soccer: The Challenge of Christian Pulisic’s Injury [TITLE]")
